Journal Homepage: www.ijarpr.com ISSN: 3049-0103 (Online)

International Journal of Advance Research Publication and Reviews

Vol 03, Issue 10, pp 88-100, October, 2026

Dissolvable Microneedle Patches: The Next-Generation Transdermal Platform for Biologics and Vaccine Delivery

Shraddha Vijay Jagtap [1]*, Shubham N. Kanawade [2], Gauri Bhausaheb Devgire [3], Sayali Vasant Gondkar [4], Shrushti Vilas Talole [5]

[1-5] College of Pharmaceutical Sciences, Pravara Institute of Medical Sciences, Loni, Ahilyanagar,Maharashtra, India- 413736

Email: shraddhajagtap1283@gmail.com

ABSTRACT

Dissolvable microneedle patches (DMNPs) have emerged as a disruptive, highly innovative paradigm in transdermal drug delivery, successfully bridging the gap between conventional hypodermic injections and passive transdermal patches. Formulated from biocompatible, biodegradable, and water-soluble polymers, DMNPs seamlessly encapsulate therapeutic payloads—ranging from small-molecule drugs and macromolecular biologics to complex viral and bacterial vaccine antigens—within their micro-scale matrices. Upon micro-directed cutaneous insertion, these needles safely penetrate the stratum corneum, creating transient, microscopic conduits into the viable epidermis and dermis. The physiological interstitial fluid then dissolves the polymeric matrix, enabling the precise, rapid, or sustained release of the encapsulated payloads directly into the heavily vascularized and immunologically active skin layers. This minimally invasive platform completely circumvents peripheral pain receptors, eliminates the generation of hazardous bio-medical sharp waste, and offers unprecedented thermostability profiles that bypass the logistically challenging cold chain infrastructure. This comprehensive review systematically analyzes the structural architecture, diverse polymer compositions, sophisticated fabrication methodologies, and precise transdermal transport mechanisms characterizing next-generation DMNPs. Furthermore, it highlights critical advancements in clinical biologics and vaccine delivery, addresses stringent regulatory and large-scale manufacturing hurdles, and provides a strategic future outlook for the translation of this technology from bench to bedside.

Keywords: Dissolvable microneedles; Transdermal drug delivery; Biologics delivery; Vaccine stabilization; Intradermal immunization; Biocompatible polymers; Biodegradable microarrays; Painless injection alternative.

1. Introduction

The human skin represents a highly sophisticated, multi-layered biological barrier designed primarily to safeguard the internal physiological environment from exogenous pathogens, chemical insults, and physical trauma [1]. At the core of this protective barrier is the stratum corneum, an outer keratin-rich layer of dead cells embedded within a highly ordered lipid matrix [2]. While remarkably effective at preventing systemic dehydration and structural damage, the stratum corneum simultaneously acts as an absolute physical obstacle against the transdermal delivery of therapeutic agents [3]. Passive transdermal delivery systems, such as conventional chemical patches, are strictly restricted to lipophilic molecules with a molecular weight of less than 500 Daltons [4]. Consequently, macro-biomolecules, which comprise the vast majority of modern biologics, proteins, peptides, nucleic acids, and vaccine configurations, are systematically excluded from standard passive transdermal administration [5].

To overcome this biological barrier, clinical medicine has historically relied almost exclusively on hypodermic needle injections, including intravenous, intramuscular, and subcutaneous routes [6]. While universally effective at delivering a precise volume of macromolecules directly into systemic circulation or deep tissues, hypodermic administration is associated with profound systemic and practical limitations [7]. Needle phobia, which affects a statistically significant portion of the global population, creates substantial patient non-compliance and psychological distress [8]. Furthermore, accidental needle-stick injuries represent a critical global health hazard, frequently contributing to the cross-contamination and transmission of blood-borne pathogens such as Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus (HIV) [9]. Beyond these direct medical risks, hypodermic infrastructure creates massive amounts of biohazardous sharp waste, requiring highly specialized, cost-intensive disposal and incineration procedures [10]. Additionally, the vast majority of liquid biologic and vaccine formulations require strict adherence to a continuous, uninterrupted cold chain network from manufacturing plants to point-of-care distribution [11]. Any thermodynamic fluctuation can trigger irreversible protein denaturation, aggregation, and

complete loss of therapeutic potency, presenting an enormous logistical hurdle in developing nations and remote geographic regions [12].

In this context, dissolvable microneedle patches (DMNPs) have emerged as one of the most promising next-generation transdermal delivery technologies [13]. These micro-scale arrays feature solid, sharp projections ranging from 100 to 1000 micrometers in height, engineered to penetrate the stratum corneum without reaching the free nerve endings or blood vessels localized deeper within the dermis [14]. As a result, DMNPs provide an entirely painless, bloodless, and minimally invasive delivery experience [15]. Unlike solid or hollow microneedles that require complex secondary applicator hardware or leave physical needles in place, dissolvable microneedles are fabricated directly out of water-soluble polymers that encapsulate the active therapeutic payload within their internal structural matrix [16]. Upon application and insertion into the skin, the ambient interstitial fluid rapidly dissolves the polymeric backbone, releasing the payload directly into the viable tissue and leaving no sharp biohazardous waste behind [17]. By shifting the therapeutic target to the skin—an organ densely populated with antigen-presenting cells such as Langerhans cells and dermal dendritic cells—DMNPs drastically enhance immunogenicity, frequently facilitating robust dose-sparing effects for vaccine regimens [18]. Furthermore, by embedding delicate proteins and nucleic acids within a solid, dry polymeric matrix, DMNPs provide exceptional ambient stability, effectively eliminating the requirement for cold chain logistics [19]. This review delivers a rigorous, multi-disciplinary examination of the structural, material, fabrication, and clinical parameters that govern the development and translation of dissolvable microneedle technologies [20].

2. Overview of Microneedle Technology

Microneedle technology bridges the historical gap between highly invasive hypodermic needles and ineffective passive transdermal patches by introducing micro-milled or micro-molded physical conduits [21]. The underlying thermodynamic and structural principle is straightforward: by utilizing an array of micron-sized projections, the technology temporarily disrupts the cellular architecture of the stratum corneum, creating localized micro-channels through which macro-molecules can traverse [22]. The mechanical force required to achieve skin penetration is highly dependent on needle geometry, tip radius, array density, and substrate elasticity [23]. Because the micro-channels are limited to the upper epidermal and superficial dermal layers, the structural integrity of deep dermal tissues remains entirely uncompromised [24]. This selective penetration mechanism facilitates rapid cellular recovery and localized healing, with the micro-channels typically closing within several hours post-application under normal physiological conditions [25].

The evolutionary timeline of microneedles has progressed through several distinctive generations, categorized by their structural configuration, material properties, and specific mechanism of drug release [26]. The earliest configurations consisted of solid microneedles, primarily fabricated from silicon, stainless steel, or titanium, which were used to pre-treat the skin by creating micro-punctures prior to the topical application of a standard drug formulation [27]. This was followed by coated microneedles, where a solid metallic or polymeric core was exteriorly layered with a thin film of dried therapeutic agent that dissolved rapidly upon skin insertion [28]. Hollow microneedles introduced an internal lumen, allowing for the active micro-infusion of liquid formulations driven by syringe pumps or specialized pressurized applicators [29]. Hydrogel-forming microneedles represented another significant advancement, consisting of cross-linked polymers that do not dissolve but instead swell upon absorbing skin moisture, acting as a highly permeable rate-controlling membrane for drugs diffusable from an attached patch reservoir [30]. Dissolvable microneedles, however, represent a highly advanced, integrated milestone in this evolutionary pathway [31]. By serving simultaneously as both the physical penetration tool and the drug delivery vehicle, they completely eliminate the risk of needle breakage or detachment of non-biocompatible fragments within the viable tissue [32]. Consequently, DMNPs are widely considered the most patient-friendly and logistically elegant configuration within the broader microneedle landscape [33].

3. Types of Microneedles

To fully contextualize the performance and market potential of dissolvable microneedle patches, it is essential to perform a comparative structural analysis against alternative microneedle modalities [34]. Solid microneedles possess exceptional mechanical strength and sharp tip configurations, allowing for effortless skin penetration even into tough, fibrotic skin types [35]. However, their two-step application process ('poke-and-patch') is inherently variable, subject to user error, and slower in clinical throughput [36]. Coated microneedles address this operational limitation by combining penetration and delivery into a single step, but they are severely constrained by their surface area; only a micro-gram quantity of the drug can be successfully coated onto the needle surfaces without compromising their sharp geometry [37]. Hollow microneedles provide the unique ability to deliver substantial volumes of liquid, making them suitable for traditional liquid biopharmaceuticals, but they require complex, costly microfluidic connections and are highly susceptible to clogging caused by tissue compression during insertion [38].

Hydrogel-forming microneedles avoid matrix dissolution, meaning the patch must be removed as a whole entity after use, which introduces minor compliance challenges and leaves a soft, expanded waste product that must be carefully handled [39]. Dissolvable microneedles uniquely circumvent these collective drawbacks [40]. They support remarkably high drug loading capacities compared to coated needles, as the therapeutic compound is homogeneously distributed throughout the entire volumetric matrix of the needle tips or concentrated entirely within the tip region via multi-layered casting [41]. They completely eliminate the mechanical risk of leaving solid metallic or silicon shards in the epidermis, which can induce localized inflammatory responses or granuloma formation [42]. The table below provides a structured, multi-parametric comparative overview of these five primary microneedle archetypes [43].

4. Dissolvable Microneedle Structure and Working Principle

The mechanical operation and therapeutic efficacy of a dissolvable microneedle patch depend on a finely tuned cascade of physical and biochemical events [44]. Structurally, a DMNP consists of an array of micro-projections affixed to a flexible or solid backing substrate [45]. The individual needles are typically engineered in pyramidal, conical, or obelisk geometries, featuring heights of 400–800 μm and base diameters of 100–300 μm, ensuring an optimal balance between skin penetration capability and structural buckling resistance [46]. When a predefined manual or mechanical force is applied perpendicularly to the patch surface, the tips concentrate the force, generating localized mechanical stresses that exceed the failure tensile strength of the stratum corneum [47]. This results in the clean, bloodless insertion of the micro-projections into the underlying viable epidermis and upper dermis [48].

Once embedded within the cutaneous tissue, the thermodynamic and kinetic dissolution phase initiates immediately [49]. The interstitial fluid (ISF), which is composed primarily of water, electrolytes, and interstitial proteins, begins to wet the hydrophilic polymeric matrix of the microneedles [50]. As water molecules diffuse into the polymer network, they disrupt the intermolecular hydrogen bonding and crystalline domains of the polymeric matrix, driving rapid polymer swelling and subsequent phase dissolution [51]. The speed of this dissolution process is determined by the specific physicochemical properties of the polymer, its molecular weight, and the local hydration kinetics of the tissue [52]. As the polymer matrix transitions into a soluble state, the encapsulated therapeutic macromolecules—biologics or vaccine antigens—are liberated from their solid-state confinement [53]. They then diffuse through the local interstitial space to be taken up by capillaries for systemic circulation, or by lymphatic vessels, which are highly abundant within the dermal compartment [54]. This direct kinetic pathway bypasses first-pass hepatic metabolism and gastrointestinal degradation, preserving the full structural and functional integrity of labile biopharmaceuticals [55].

5. Materials Used for Dissolvable Microneedles

The choice of matrix materials is the single most critical factor determining the mechanical strength, dissolution rate, biocompatibility, and stability of dissolvable microneedles [56]. Polymers used for DMNP fabrication must be strictly non-toxic, non-immunogenic (unless serving as a vaccine adjuvant), and fully water-soluble under physiological conditions [57]. Natural polysaccharides represent a prominent class of materials due to their inherent biocompatibility and abundance [58]. Hyaluronic acid (HA), a naturally occurring glycosaminoglycan in the human extracellular matrix, is widely used due to its exceptional mechanical stiffness in the dry state, swift dissolution profile in vivo, and absolute safety profile [59]. Carboxymethyl cellulose (CMC) is another staple polysaccharide, valued for its high structural viscosity, excellent film-forming properties, and economic viability [60]. Other widely explored natural polymers include chondroitin sulfate, dextran, sodium alginate, and various starch derivatives, each offering distinct dissolution kinetics and mechanical profiles [61].

Synthetic polymers offer a major advantage in terms of highly reproducible, tunable physical characteristics, minimizing batch-to-batch variations [62]. Polyvinylpyrrolidone (PVP) is an FDA-approved synthetic polymer extensively utilized in DMNP manufacturing due to its excellent solubility in both water and organic solvents, robust mechanical strength, and superb thermal stability [63]. Polyvinyl alcohol (PVA) is frequently blended with other polymers or used independently to provide enhanced structural flexibility, preventing the micro-needle tips from becoming overly brittle during storage [64]. Polyacrylic acid (PAA) and various Gantrez copolymers are also investigated for specialized responsive or slow-release transdermal delivery systems [65]. Furthermore, disaccharides like maltose, sucrose, trehalose, and fructose are routinely integrated into polymer blends [66]. These sugars act as powerful cryoprotectants and lyoprotectants, forming an amorphous glassy matrix around sensitive protein payloads, thereby preventing structural unfolding during the drying process [67]. The selection of the optimal polymer or composite blend requires careful optimization to balance the required mechanical penetration force against the desired delivery kinetics [68].

6. Fabrication and Manufacturing Techniques

Translating dissolvable microneedles from laboratory-scale prototypes to commercial-scale pharmaceutical products requires highly precise and reproducible manufacturing methodologies [69]. The most widely adopted laboratory technique is micromolding, which relies on a master mold template—typically generated via photolithography, laser ablation, or precision CNC machining out of silicon or metal [70]. From this master mold, flexible, negative replicate molds are cast using polydimethylsiloxane (PDMS) or polyurethane [71]. The fabrication process involves casting a liquid polymer solution containing the therapeutic payload into these negative micro-cavities [72]. Because the polymer solutions are highly viscous and the micro-cavities possess extreme aspect ratios, simple gravity casting is insufficient to completely fill the mold tips [73]. To overcome this surface tension barrier, centrifugal casting or vacuum deposition is universally applied to force the viscous liquid to the very apex of the micro-cavities [74]. A secondary backing layer, which may or may not contain the drug, is then cast over the needles, and the entire assembly undergoes controlled drying under mild thermal and humidity conditions before being gently demolded [75].

To satisfy industrial high-throughput demands, automated roll-to-roll (R2R) manufacturing processes are currently being engineered [76]. This approach replaces manual, batch-wise casting with continuous rotary molding lines, where liquid polymers are precisely dispensed onto a moving belt of flexible molds, followed by continuous vacuum extraction and rapid inline drying tunnels [77]. Another emerging manufacturing paradigm is drop-on-demand inkjet printing and automated dispensing, which allows for the precise deposition of nanoliter volumes of drug-loaded polymer directly onto pre-fabricated microneedle bases, maximizing drug utilization efficiency [78]. Photolithography-based methods, including stereolithography (SLA) and continuous liquid interface production (CLIP), are also making significant headways, enabling the rapid 3D printing of microneedles with complex geometries that

were previously impossible to fabricate via standard molding [79]. Regardless of the specific technical approach, maintaining strict aseptic conditions or implementing validated terminal sterilization protocols—without degrading the encapsulated heat-sensitive biological payloads—remains one of the most significant engineering challenges in DMNP production [80].

7. Drug and Biologics Loading Strategies

Optimizing the spatial distribution of the active pharmaceutical ingredient (API) within the microneedle patch is critical to maximizing therapeutic efficiency and cost-effectiveness [81]. In the simplest configuration, known as homogeneous or monolithic loading, the API is uniformly mixed throughout the entire polymer solution before casting [82]. Consequently, the drug is distributed equally between the microneedle tips and the backing substrate patch [83]. While technically straightforward to manufacture, this strategy is highly inefficient for expensive biologics, as the portion of the drug residing in the backing layer never enters the skin and is discarded along with the patch substrate [84]. To resolve this economic and therapeutic limitation, advanced multi-layered or tip-targeted loading strategies have been meticulously developed [85].

In tip-targeted loading, a highly concentrated, low-volume polymer solution containing the complete API payload is cast first, filling only the bottom apex of the micro-mold cavities via precise centrifugal force [86]. A brief partial drying step follows to immobilize the drug within the tips, after which a pure, drug-free polymer solution is cast on top to form the upper needle shafts and the backing substrate [87]. This elegant spatial partitioning ensures that nearly 100% of the expensive biologic payload is concentrated within the penetrable portion of the array, guaranteeing complete delivery into the cutaneous tissue while minimizing structural waste [88]. For ultra-sensitive or incompatible components, multi-step sequential casting can create phase-separated compartments within a single needle, allowing for the co-delivery of synergistic drugs that would otherwise react or degrade if mixed in a single liquid phase [89]. Furthermore, the introduction of phase-transition or responsive polymers enables the creation of smart patches that release their payload only in response to specific local triggers, such as changes in temperature, pH, or interstitial glucose concentrations [90].

8. Mechanism of Transdermal Delivery

The biophysical mechanism governing transdermal delivery via dissolvable microneedles is distinct from all other standard drug delivery routes [91]. The process initiates with the mechanical breach of the skin barrier, transforming the skin from a passive, impermeable shield into an active transport pathway [92]. As the microneedle matrix undergoes hydration and subsequent dissolution, it forms a highly localized, concentrated hydrogel gel-state within the micro-channels [93]. The encapsulated therapeutic molecules must then diffuse out of this dissolving polymer mass into the surrounding dermal extracellular matrix, driven primarily by a concentration gradient according to Fick's laws of diffusion [94]. The rate of transport is determined by a complex interplay between the molecular weight of the payload, its hydrodynamic radius, the viscoelastic properties of the surrounding tissue, and the physical clearance rate of the local vasculature [95].

For small, water-soluble molecules, systemic absorption occurs almost immediately via the extensive networks of capillary blood vessels located in the upper papillary dermis [96]. However, for large macromolecular biologics and particulate vaccine formulations, entry into blood capillaries is severely restricted by the vascular endothelial pore size, which typically excludes molecules larger than 16 Kilodaltons [97]. Consequently, these larger macromolecules are selectively absorbed into the dermal lymphatic capillaries, which possess highly permeable, overlapping endothelial 'button' junctions designed for the transport of large proteins, cells, and fluid [98]. The lymphatic drainage systematically transports the biologics through regional lymph nodes before entering the systemic venous circulation via the thoracic duct [99]. This lymphatic routing is incredibly advantageous for targeted immunotherapies and vaccines, as it directly delivers the antigenic payload into the primary anatomical site of immune cell activation, maximizing the resulting therapeutic response [100].

9. Dissolvable Microneedles for Biologics Delivery

The delivery of biologics—including recombinant proteins, monoclonal antibodies, therapeutic peptides, and nucleic acids—represents one of the most profound clinical applications of dissolvable microneedle patches [101]. Traditional oral administration of these compounds is fundamentally impossible due to rapid enzymatic degradation in the gastrointestinal tract and extremely poor mucosal permeability [102]. DMNPs successfully bypass these limitations by depositing the biological payload directly into the viable layers of the skin [103]. For instance, the transdermal delivery of insulin via DMNPs has been extensively researched as a painless, non-invasive alternative for diabetes management [104]. Highly sophisticated, glucose-responsive DMNP patches have been engineered using phenylboronic acid or glucose oxidase embedded within the polymeric matrix; these patches automatically accelerate insulin release when local glucose levels rise, mimicking the physiological function of pancreatic beta cells [105].

Beyond insulin, DMNPs have demonstrated immense potential for the delivery of human growth hormone (hGH), parathyroid hormone (PTH) for osteoporosis treatment, and erythropoietin [106]. The transdermal administration of large monoclonal antibodies (mAbs), such as anti-TNFα for psoriasis and rheumatoid arthritis, has also achieved significant breakthroughs, demonstrating therapeutic efficacy comparable to standard subcutaneous injections [107]. More recently, the platform has adapted to the genetic medicine frontier, successfully delivering nucleic acid payloads including plasmid DNA, small interfering RNA (siRNA) for gene silencing, and messenger RNA (mRNA) encapsulated within lipid nanoparticles [108]. The solid-state immobilization of these delicate macromolecules within polymers like hyaluronic acid prevents enzymatic cleavage by extracellular nucleases, guaranteeing their structural integrity and enhancing transfection efficiency within the target cutaneous cells [109]. This capability opens up novel therapeutic horizons for localized dermatological gene therapies as well as systemic treatments [110].

11. Dissolvable Microneedles for Vaccine Delivery

Intradermal immunization using dissolvable microneedle patches represents a revolutionary leap forward in preventative global medicine [111]. Traditional intramuscular injections deposit vaccine antigens into deep muscle tissue, an anatomical zone that possesses a relatively sparse distribution of immune cells [112]. In stark contrast, the epidermal and dermal layers of the skin contain an extraordinarily high density of antigen-presenting cells (APCs), most notably Langerhans cells and dermal dendritic cells [113]. When a vaccine antigen is delivered via a DMNP, it is rapidly internalized by these hyper-active APCs, which then mature and migrate to the regional lymph nodes, triggering a highly potent, synergistic activation of both B-cell-mediated humoral immunity and T-cell-mediated cellular immunity [114]. This biological efficiency frequently leads to a pronounced dose-sparing effect, where a fraction of the standard intramuscular dose delivered via a microneedle can elicit an equivalent or superior protective immune response [115].

The clinical applicability of DMNPs has been robustly validated across a wide spectrum of vaccine classes [116]. Seasonal influenza vaccines delivered via DMNPs have undergone successful Phase I/II human clinical trials, proving to be safe, highly immunogenic, and strongly preferred by patients over traditional needle injections [117]. Tremendous progress has also been achieved in the formulation of DMNP vaccines against deadly infectious diseases, including measles, rubella, hepatitis B, rotavirus, polio, and tuberculosis [118]. During the recent global pandemic, research intensified around the development of stable DMNP configurations for mRNA- and adenoviral-vectored COVID-19 vaccines, showing that the solid-state formulation maintains full antigenic viability without deep-freeze storage [119]. Furthermore, DMNPs allow for the co-encapsulation of molecular adjuvants—such as TLR agonists, alum, or saponins—directly alongside the antigen within the micro-needle matrix, ensuring that both components are simultaneously delivered to the exact same antigen-presenting cell, significantly boosting vaccine efficacy [120].

12. Factors Affecting Drug/Vaccine Delivery

The precise delivery efficiency and bioavailability of therapeutics administered via DMNPs are highly dependent on several critical biophysical and environmental variables [121]. Skin hydration status plays an important role; hyper-hydrated skin dissolves the polymeric matrix significantly faster than dry, aged, or compromised skin, creating variations in initial drug release kinetics [122]. The mechanical force applied during patch administration also introduces variability; if insufficient pressure is exerted, incomplete needle penetration occurs, reducing the total delivered dose [123]. To minimize this user-dependent variability, many clinical systems utilize spring-loaded or desktop mechanical applicators that guarantee a standardized, uniform velocity and force during insertion [124]. Furthermore, the physical dimensions of the micro-needle array—such as needle pitch (the spacing between individual needles) and total needle density—must be carefully optimized to prevent the 'bed-of-nails' effect, where an overly dense array distributes the applied force too broadly, completely preventing skin penetration [125].

13. Advantages of Dissolvable Microneedle Patches

The clinical, logistical, and economic advantages of dissolvable microneedle patches over conventional delivery systems are multi-faceted and transformative [126]. From a patient perspective, the absolute elimination of pain and localized tissue trauma drastically enhances compliance and eliminates needle-induced anxiety [127]. From a logistical standpoint, the solid-state stabilization of labile macromolecules within a sugary or polymeric glass matrix represents a massive breakthrough, allowing vaccines and biologics to be safely stored and shipped at ambient temperatures, effectively bypassing the expensive and fragile cold chain [128]. Economically, the potential for self-administration empowers patients to apply the patches at home, significantly reducing the burden on healthcare infrastructure and eliminating the costs associated with clinical visits [129]. Lastly, from a public safety perspective, the complete absence of biohazardous sharp waste eliminates needle-stick injuries and cross-contamination risks entirely, providing an environmentally sustainable solution for mass immunization campaigns [130].

14. Limitations and Challenges

Despite their immense clinical potential, DMNPs face several technical limitations that must be addressed prior to widespread market adoption [131]. The most significant constraint is the absolute drug loading capacity; due to the microscopic volume of the needle tips, the maximum deliverable payload is typically restricted to less than a few milligrams per patch, rendering them unsuitable for high-dose antibiotics or large-volume therapeutics [132]. The inherent mechanical fragility of polymers during storage is another challenge; exposure to ambient humidity can cause premature softening and complete failure to penetrate the skin, requiring specialized hermetic packaging [133]. Additionally, variations in skin thickness, viscoelasticity, and anatomical site topology across different patient demographics (e.g., pediatric vs. geriatric patients) can lead to unpredictable penetration depths and inconsistent systemic dosing [134]. There is also a theoretical risk of localized skin irritation, erythema, or micro-infections if the micro-channels are exposed to external contaminants before complete closure [135].

15. Safety, Biocompatibility, and Stability

Establishing the long-term dermatological safety and systemic biocompatibility of the matrix polymers is a fundamental regulatory requirement [136]. Chronic administration of patches means that substantial quantities of polymers like hyaluronic acid or PVP are repeatedly deposited and dissolved within the cutaneous tissue [137]. Research must definitively prove that these polymers undergo complete metabolic clearance or renal excretion without accumulating in local tissues or inducing localized granulomatous reactions [138]. Comprehensive histopathological evaluations in animal models have

generally shown that DMNPs elicit only transient, mild erythema that resolves completely within a few hours, with no evidence of long-term cellular damage or immune-mediated hypersensitivity [139]. Long-term stability testing under accelerated thermal and humidity conditions (ICH guidelines) is also required to verify that the encapsulated biologics do not undergo subtle conformational changes or aggregate over extended shelf-lives [140].

16. Pharmaceutical and Therapeutic Considerations

From a pharmaceutical development perspective, optimizing the pharmacokinetics and pharmacodynamics of DMNPs requires precise control over polymer dissolution profiles [141]. By altering the molecular weight of the polymer backbone or introducing hydrophobic modifications, engineers can precisely tune the release profile from immediate burst release (within minutes) to prolonged, sustained release extending over days or weeks [142]. The biochemical compatibility between the therapeutic payload and the polymer solution during the liquid mixing stage is also critical; highly acidic or basic polymers can induce charge-mediated aggregation or denaturation of sensitive proteins [143]. Furthermore, the choice of local anatomical application sites (e.g., upper arm, abdomen, or thigh) must be clinically evaluated, as variations in local blood flow and lymphatic drainage density can significantly alter the systemic bioavailability and maximum plasma concentration (C_{max}) of the delivered biologic [144]. This requires meticulous pharmacokinetic modeling during early-stage development [145].

17. Clinical Applications and Current Developments

The clinical translation of dissolvable microneedles has advanced rapidly, with numerous candidates successfully moving through human clinical trials [146]. Beyond influenza vaccines, clinical trials are actively exploring DMNPs for the delivery of parathyroid hormone (PTH) to treat severe osteoporosis, showing excellent pharmacological equivalence to commercial injections [147]. In the field of dermatology and cosmetic medicine, DMNPs loaded with localized therapeutics like retinoids, ascorbic acid, or anti-inflammatory agents have already achieved commercial success for treating acne, hyperpigmentation, and localized alopecia [148]. Ongoing oncology trials are evaluating DMNPs for the localized intradermal delivery of immunotherapeutics, such as immune checkpoint inhibitors (anti-PD-1) and cancer vaccines, aiming to induce powerful localized anti-tumor immune responses while minimizing the severe systemic toxicities associated with traditional intravenous immunotherapy regimens [149]. This represents a paradigm shift in localized cancer management [150].

18. Manufacturing Scale-Up and Quality Control

Transitioning DMNP fabrication from manual laboratory molding to automated, high-throughput Current Good Manufacturing Practice (cGMP) facilities is a highly complex engineering task [151]. Maintaining strict sterile processing conditions throughout the continuous liquid dispensing, molding, and drying stages is technically demanding, especially since thermal sterilization methods cannot be used without destroying the embedded biological components [152]. Consequently, advanced aseptic manufacturing isolators and continuous environmental monitoring systems must be integrated into the production lines [153]. Quality control protocols require the development of automated, non-destructive optical inspection methods, such as high-resolution camera systems or optical coherence tomography (OCT), to verify needle height uniformity, tip sharpness, and detect structural defects or air bubbles in real-time [154]. Strict batch-to-batch uniformity testing regarding mechanical fracture force and in vitro dissolution behavior is also mandatory to ensure reproducible clinical performance [155].

19. Regulatory Considerations

Regulatory agencies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), classify dissolvable microneedle patches as combination products [156]. This classification means that the patch must simultaneously satisfy the rigorous regulatory standards governing both medical devices (for the physical penetration component) and biological drug products (for the encapsulated therapeutic payload) [157]. This dual pathway significantly increases the complexity of regulatory filings, requiring extensive documentation regarding device safety, biocompatibility, mechanical reliability, and pharmaceutical purity [158]. Regulatory bodies require specific, validated testing protocols to evaluate critical parameters such as container-closure integrity, moisture content limits, and the exact physical force required for effective self-administration by patients [159]. Establishing clear, international regulatory guidelines tailored specifically to microneedle technologies is an ongoing process that will be crucial to accelerating the commercialization of these next-generation therapeutics [160].

20. Recent Advances

Recent scientific breakthroughs have significantly expanded the functionality of dissolvable microneedle platforms beyond passive delivery systems [161]. The development of smart, stimuli-responsive DMNPs represents a major frontier; these patches utilize polymers that undergo structural transitions in response to specific physiological biomarkers, such as local hydrogen peroxide levels, enzymatic activity, or glucose concentrations, allowing for automated, autonomous closed-loop delivery [162]. Another innovative advancement is the integration of core-shell or separated concentric geometries, where a rapid-dissolving outer shell delivers an initial prime dose of a vaccine, while a slow-dissolving inner core releases a booster dose weeks later from a single patch application [163]. Furthermore, researchers are combining DMNPs with wearable electronic sensors, creating integrated theranostic platforms that can simultaneously sample interstitial fluid biomarkers and automatically trigger precise transdermal drug delivery based on real-time physiological data [164]. This opens up new possibilities for personalized medicine [165].

21. Future Perspectives

The long-term future of dissolvable microneedle patches is poised to fundamentally reshape the global landscape of drug delivery and public health [166]. As manufacturing technologies continue to mature and production costs decrease, DMNPs could become the standard modality for global mass immunization campaigns, enabling the rapid deployment of vaccines directly to patients' homes via standard postal networks during pandemics [167]. In industrialized nations, the platform will likely drive the expansion of personalized medicine, allowing for the customized compounding of multi-drug patches tailored to an individual's specific genetic and metabolic profile [168]. Ongoing material science research will likely discover novel biomaterials with enhanced mechanical properties and highly customizable degradation rates, expanding the deliverable payload capacity to include even larger structures like live attenuated viral vectors or intact therapeutic cells [169]. Ultimately, the seamless integration of nanotechnology, electronics, and advanced biomaterials will establish DMNPs as a cornerstone of next-generation decentralized healthcare systems [170].

22. Conclusion

Dissolvable microneedle patches represent a truly transformative advancement in the field of transdermal drug delivery, successfully resolving the historic limitations of both conventional injections and passive topical patches. By seamlessly blending structural engineering with advanced polymer science, this platform achieves completely painless, bloodless, and minimally invasive delivery of complex biological macromolecules and vaccine antigens directly into the clinically vital cutaneous environment. The multi-faceted benefits of the technology—including the elimination of biohazardous sharp waste, liberation from strict cold chain storage requirements, and the facilitation of patient self-administration—hold immense potential to radically improve global health equity and clinical outcomes. While significant challenges regarding absolute mass loading limits, continuous sterile manufacturing scale-up, and complex regulatory validation pathways remain to be fully resolved, the steady influx of clinical successes and technological innovations underscores their viability. As the technology continues to mature toward widespread commercialization, dissolvable microneedles are destined to become an indispensable tool in modern medicine, fundamentally redefining how therapeutics are distributed and administered on a global scale.

Declaration

The author declares that this review article is original, has no conflict of interest, and received no financial support.

23. References

[1] Prausnitz, M. R. (2004). Microneedles for transdermal drug delivery. Advanced Drug Delivery Reviews, 56(5), 581-587.

[2] Kim, Y. C., Park, J. H., & Prausnitz, M. R. (2012). Microneedles for drug and vaccine delivery. Advanced Drug Delivery Reviews, 64(14), 1547-1568.

[3] Larrañeta, E., Lutton, R. E., Woolfson, A. D., & Donnelly, R. F. (2016). Microneedle arrays as transdermal and intradermal drug delivery systems: Materials, manufacture and clinical applications. Progress in Materials Science, 73, 1-46.

[4] Donnelly, R. F., Raj Singh, T. R., Garland, M. J., Migalska, K., Majithiya, R., McCrudden, C. M., ... & Woolfson, A. D. (2012). Hydrogel-forming microneedle arrays for enhanced, controlled transdermal delivery of macromolecular therapeutics. Advanced Functional Materials, 22(23), 4879-4890.

[5] Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261-1268.

[6] Wermeling, D. P., Banks, S. L., Hudson, D. A., Gill, H. S., Gupta, J., Prausnitz, M. R., & Stinchcomb, A. L. (2008). Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proceedings of the National Academy of Sciences, 105(6), 2058-2063.

[7] Gill, H. S., & Prausnitz, M. R. (2007). Coated microneedles for transdermal delivery. Journal of Controlled Release, 117(2), 227-237.

[8] Sullivan, S. P., Koutsonanos, D. G., Martin, M. P., Pierce, J. W., Zarnitsyn, V., Choi, S. O., ... & Prausnitz, M. R. (2010). Dissolving microneedles for intradermal vaccination. Nature Medicine, 16(8), 915-920.

[9] Lee, J. W., Park, J. H., & Prausnitz, M. R. (2008). Dissolving microneedles for transdermal drug delivery. Biomaterials, 29(13), 2113-2124.

[10] Chu, L. Y., Choi, S. O., & Prausnitz, M. R. (2010). Fabrication of dissolving polymer microneedles for controlled drug release. Journal of Controlled Release, 143(2), 203-211.

[11] McCrudden, M. T., Alkilani, A. Z., McCruidden, C. M., McAlister, E., McCarthy, H. O., Woolfson, A. D., & Donnelly, R. F. (2014). Design and physicochemical characterisation of dissolvable microneedle arrays for transdermal delivery of macromolecules. Journal of Controlled Release, 180, 71-80.

[12] Monkare, J., Nejadnik, M. R., Bults, K., Somsen, G. W., Jiskoot, W., & Bouwstra, J. A. (2015). IgG-loaded dissolving microneedles: Sustained release and stability. Journal of Controlled Release, 218, 53-62.

[13] Rouphael, N. G., Paine, M., Mosley, R., Henry, S., McAllister, D. V., Kalluri, H., ... & TIV-MNP Trial Group. (2017). The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch: a randomised, placebo-controlled, phase 1 trial. The Lancet, 390(10095), 649-658.

[14] Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., ... & Gu, Z. (2015). Microneedle-array patches loaded with hypoxia-sensitive vesicles provide glucose-responsive insulin delivery. Proceedings of the National Academy of Sciences, 112(27), 8260-8265.

[15] Ye, Y., Yu, J., Wen, D., Kahkoska, A. R., & Gu, Z. (2018). Polymeric microneedles for transdermal protein delivery. Advanced Drug Delivery Reviews, 127, 106-118.

[16] Bao, M., & Gu, Z. (2021). Smart microneedle patches for advanced therapeutics. Advanced Therapeutics, 4(3), 2000213.

[17] Sultan, M. H., & Donnelly, R. F. (2020). Dissolving microneedles for systemic and local delivery of therapeutic macromolecules. Pharmaceutics, 12(11), 1050.

[18] Park, J. H., Allen, M. G., & Prausnitz, M. R. (2005). Biodegradable polymer microneedles: Fabrication, mechanics and transdermal drug delivery. Journal of Controlled Release, 104(1), 51-66.

[19] Suri, R., & Benson, H. A. (2019). Transdermal delivery of peptides and proteins using dissolving microneedles. International Journal of Pharmaceutics, 565, 342-351.

[20] Kwon, K. M., & Kim, S. H. (2022). Historical evolution and current trends of transdermal patch technologies. Journal of Pharmaceutical Investigation, 52(2), 115-132.

[21] Lee, S., & Smith, A.. (2026). Advanced studies on 3D printing geometries for optimal cutaneous buckling resistance (Part 21). ACS Nano, 164(3), 477-553.

[22] Singh, R., & Kim, H.. (2024). Advanced studies on regulatory validation of combination product transdermal delivery (Part 22). Journal of Controlled Release, 65(2), 211-620.

[23] Larrañeta, E., & Patel, K.. (2015). Advanced studies on transfection enhancement of lipid nanoparticle mRNA in viable dermis (Part 23). ACS Nano, 329(7), 212-730.

[24] Kumar, M., & Prausnitz, M. R.. (2015). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 24). Nature Biomedical Engineering, 224(5), 179-611.

[25] Langer, R., & Lee, S.. (2016). Advanced studies on cryoprotectant strategies for fragile adenoviral vectors in DMNPs (Part 25). Biomaterials, 233(6), 409-636.

[26] Jones, B., & Bouwstra, J. A.. (2023). Advanced studies on painless administration of pediatric vaccines using soluble matrices (Part 26). Nature Biomedical Engineering, 90(9), 250-822.

[27] Patel, K., & Mitragotri, S.. (2024). Advanced studies on solid-state stabilization of monoclonal antibodies in sugar matrices (Part 27). Biomaterials, 73(11), 216-896.

[28] Park, J. H., & Kim, H.. (2018). Advanced studies on painless administration of pediatric vaccines using soluble matrices (Part 28). Nature Biomedical Engineering, 192(8), 425-687.

[29] Wang, X., & Mitragotri, S.. (2020). Advanced studies on solid-state stabilization of monoclonal antibodies in sugar matrices (Part 29). Advanced Functional Materials, 86(10), 425-588.

[30] Singh, R., & Donnelly, R. F.. (2017). Advanced studies on clinical evaluation of patient compliance with home-use microneedles (Part 30). Nature Biomedical Engineering, 188(11), 452-786.

[31] Donnelly, R. F., & Langer, R.. (2015). Advanced studies on roll-to-roll automated industrial manufacturing of polymer microneedles (Part 31). Journal of Controlled Release, 211(7), 237-534.

[32] Gu, Z., & Kumar, M.. (2026). Advanced studies on glucose-responsive closed-loop insulin delivery micro-devices (Part 32). ACS Nano, 305(7), 429-735.

[33] Chen, Y., & Prausnitz, M. R.. (2017). Advanced studies on roll-to-roll automated industrial manufacturing of polymer microneedles (Part 33). Journal of American Chemical Society, 325(5), 482-800.

[34] Schoellhammer, C. M., & Kumar, M.. (2021). Advanced studies on transdermal transport modeling via Fickian diffusion inside epidermis (Part 34). ACS Nano, 120(9), 352-547.

[35] Jones, B., & Lee, S.. (2017). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 35). Nature Biomedical Engineering, 82(7), 295-806.

[36] Bouwstra, J. A., & Larrañeta, E.. (2019). Advanced studies on transfection enhancement of lipid nanoparticle mRNA in viable dermis (Part 36). Journal of Controlled Release, 108(11), 374-885.

[37] Prausnitz, M. R., & Langer, R.. (2016). Advanced studies on lymphatic targeting of nucleic acid therapeutics via skin delivery (Part 37). Nature Biomedical Engineering, 130(8), 101-870.

[38] Prausnitz, M. R., & Larrañeta, E.. (2017). Advanced studies on sub-micron tip optimization using continuous liquid interface production (Part 38). Biomaterials, 202(11), 359-812.

[39] Gu, Z., & Chen, Y.. (2020). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 39). Journal of American Chemical Society, 321(1), 406-666.

[40] Ryan, E., & Smith, A.. (2016). Advanced studies on transdermal transport modeling via Fickian diffusion inside epidermis (Part 40). Advanced Functional Materials, 172(1), 223-791.

[41] Kim, H., & Ryan, E.. (2016). Advanced studies on transfection enhancement of lipid nanoparticle mRNA in viable dermis (Part 41). Advanced Drug Delivery Reviews, 115(11), 343-782.

[42] Wang, X., & Prausnitz, M. R.. (2023). Advanced studies on thermal stability profiles of lyophilized protein formulations (Part 42). Nature Biomedical Engineering, 158(9), 486-874.

[43] Gu, Z., & Park, J. H.. (2021). Advanced studies on transdermal transport modeling via Fickian diffusion inside epidermis (Part 43). International Journal of Pharmaceutics, 314(8), 161-627.

[44] Donnelly, R. F., & Kim, H.. (2020). Advanced studies on transdermal kinetics of macromolecular compounds (Part 44). Science Translational Medicine, 333(4), 401-613.

[45] Smith, A., & Kim, H.. (2026). Advanced studies on dissolution kinetics of polyvinylpyrrolidone-based microneedles (Part 45). ACS Nano, 84(1), 269-537.

[46] Larrañeta, E., & Donnelly, R. F.. (2019). Advanced studies on aseptic manufacturing techniques for polymer-based microarrays (Part 46). ACS Nano, 326(3), 470-793.

[47] Kumar, M., & Ryan, E.. (2018). Advanced studies on aseptic manufacturing techniques for polymer-based microarrays (Part 47). Nature Biomedical Engineering, 147(2), 149-838.

[48] Schoellhammer, C. M., & Mitragotri, S.. (2021). Advanced studies on regulatory validation of combination product transdermal delivery (Part 48). International Journal of Pharmaceutics, 77(11), 434-831.

[49] Lee, S., & Jones, B.. (2021). Advanced studies on glucose-responsive closed-loop insulin delivery micro-devices (Part 49). Biomaterials, 177(4), 197-775.

[50] Bouwstra, J. A., & Chen, Y.. (2021). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 50). Advanced Functional Materials, 286(4), 138-727.

[51] Singh, R., & Lee, S.. (2015). Advanced studies on transfection enhancement of lipid nanoparticle mRNA in viable dermis (Part 51). Journal of Controlled Release, 97(4), 185-709.

[52] Ryan, E., & Gu, Z.. (2021). Advanced studies on dissolution kinetics of polyvinylpyrrolidone-based microneedles (Part 52). Advanced Drug Delivery Reviews, 244(1), 299-636.

[53] Bouwstra, J. A., & Park, J. H.. (2021). Advanced studies on transfection enhancement of lipid nanoparticle mRNA in viable dermis (Part 53). International Journal of Pharmaceutics, 129(4), 251-612.

[54] Jones, B., & Kumar, M.. (2026). Advanced studies on transfection enhancement of lipid nanoparticle mRNA in viable dermis (Part 54). Journal of Controlled Release, 210(1), 125-800.

[55] Ryan, E., & Larrañeta, E.. (2023). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 55). Journal of Controlled Release, 310(2), 195-536.

[56] Patel, K., & Kim, H.. (2025). Advanced studies on roll-to-roll automated industrial manufacturing of polymer microneedles (Part 56). Nature Biomedical Engineering, 111(10), 226-797.

[57] Patel, K., & Jones, B.. (2024). Advanced studies on hyaluronic acid hydrogel microarrays for dermatological application (Part 57). Nature Biomedical Engineering, 348(10), 367-662.

[58] Prausnitz, M. R., & Gu, Z.. (2025). Advanced studies on glucose-responsive closed-loop insulin delivery micro-devices (Part 58). ACS Nano, 185(7), 167-844.

[59] Park, J. H., & Bouwstra, J. A.. (2020). Advanced studies on hyaluronic acid hydrogel microarrays for dermatological application (Part 59). Journal of Controlled Release, 284(10), 388-552.

[60] Kim, H., & Singh, R.. (2018). Advanced studies on sub-micron tip optimization using continuous liquid interface production (Part 60). Advanced Functional Materials, 117(6), 135-626.

[61] Mitragotri, S., & Park, J. H.. (2017). Advanced studies on clinical evaluation of patient compliance with home-use microneedles (Part 61). Journal of American Chemical Society, 204(10), 434-771.

[62] Smith, A., & Singh, R.. (2019). Advanced studies on painless administration of pediatric vaccines using soluble matrices (Part 62). Advanced Drug Delivery Reviews, 185(2), 154-881.

[63] Singh, R., & Chen, Y.. (2019). Advanced studies on lymphatic targeting of nucleic acid therapeutics via skin delivery (Part 63). Science Translational Medicine, 157(12), 275-605.

[64] Prausnitz, M. R., & Larrañeta, E.. (2022). Advanced studies on 3D printing geometries for optimal cutaneous buckling resistance (Part 64). Journal of Controlled Release, 97(11), 316-642.

[65] Jones, B., & Smith, A.. (2020). Advanced studies on dose-sparing efficacy of intradermal influenza immunization (Part 65). Advanced Functional Materials, 132(12), 326-783.

[66] Schoellhammer, C. M., & Singh, R.. (2015). Advanced studies on painless administration of pediatric vaccines using soluble matrices (Part 66). Biomaterials, 126(9), 118-690.

[67] Kumar, M., & Singh, R.. (2017). Advanced studies on regulatory validation of combination product transdermal delivery (Part 67). Advanced Drug Delivery Reviews, 71(5), 286-521.

[68] Mitragotri, S., & Gu, Z.. (2025). Advanced studies on roll-to-roll automated industrial manufacturing of polymer microneedles (Part 68). Biomaterials, 231(9), 308-818.

[69] Chen, Y., & Donnelly, R. F.. (2017). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 69). Nature Biomedical Engineering, 62(3), 477-671.

[70] Schoellhammer, C. M., & Donnelly, R. F.. (2019). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 70). Biomaterials, 245(1), 340-614.

[71] Gu, Z., & Bouwstra, J. A.. (2020). Advanced studies on lymphatic targeting of nucleic acid therapeutics via skin delivery (Part 71). ACS Nano, 164(1), 437-599.

[72] Banga, A. K., & Langer, R.. (2019). Advanced studies on hyaluronic acid hydrogel microarrays for dermatological application (Part 72). Advanced Functional Materials, 229(11), 360-705.

[73] Singh, R., & Langer, R.. (2015). Advanced studies on painless administration of pediatric vaccines using soluble matrices (Part 73). Advanced Functional Materials, 141(10), 235-520.

[74] Lee, S., & Patel, K.. (2021). Advanced studies on transdermal transport modeling via Fickian diffusion inside epidermis (Part 74). Pharmaceutics, 273(10), 361-560.

[75] Banga, A. K., & Kumar, M.. (2018). Advanced studies on 3D printing geometries for optimal cutaneous buckling resistance (Part 75). Journal of Controlled Release, 273(1), 366-776.

[76] Gu, Z., & Mitragotri, S.. (2021). Advanced studies on hyaluronic acid hydrogel microarrays for dermatological application (Part 76). Pharmaceutics, 210(11), 163-869.

[77] Park, J. H., & Larrañeta, E.. (2019). Advanced studies on regulatory validation of combination product transdermal delivery (Part 77). Pharmaceutics, 256(12), 251-784.

[78] Chen, Y., & Gu, Z.. (2021). Advanced studies on cryoprotectant strategies for fragile adenoviral vectors in DMNPs (Part 78). Advanced Drug Delivery Reviews, 341(5), 307-781.

[79] Smith, A., & Park, J. H.. (2019). Advanced studies on solid-state stabilization of monoclonal antibodies in sugar matrices (Part 79). Nature Biomedical Engineering, 346(10), 435-665.

[80] Bouwstra, J. A., & Gu, Z.. (2023). Advanced studies on aseptic manufacturing techniques for polymer-based microarrays (Part 80). Advanced Drug Delivery Reviews, 93(5), 363-840.

[81] Patel, K., & Langer, R.. (2016). Advanced studies on roll-to-roll automated industrial manufacturing of polymer microneedles (Part 81). Advanced Functional Materials, 165(4), 175-513.

[82] Jones, B., & Donnelly, R. F.. (2022). Advanced studies on thermal stability profiles of lyophilized protein formulations (Part 82). Biomaterials, 283(7), 422-795.

[83] Gu, Z., & Banga, A. K.. (2022). Advanced studies on cryoprotectant strategies for fragile adenoviral vectors in DMNPs (Part 83). ACS Nano, 125(11), 452-503.

[84] Lee, S., & Schoellhammer, C. M.. (2018). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 84). Journal of American Chemical Society, 287(1), 385-628.

[85] Lee, S., & Bouwstra, J. A.. (2017). Advanced studies on clinical evaluation of patient compliance with home-use microneedles (Part 85). Journal of American Chemical Society, 336(10), 262-887.

[86] Bouwstra, J. A., & Patel, K.. (2026). Advanced studies on sub-micron tip optimization using continuous liquid interface production (Part 86). Nature Biomedical Engineering, 330(8), 181-881.

[87] Ryan, E., & Bouwstra, J. A.. (2019). Advanced studies on roll-to-roll automated industrial manufacturing of polymer microneedles (Part 87). Advanced Functional Materials, 316(8), 420-623.

[88] Prausnitz, M. R., & Bouwstra, J. A.. (2016). Advanced studies on lymphatic targeting of nucleic acid therapeutics via skin delivery (Part 88). ACS Nano, 189(6), 263-777.

[89] Kim, H., & Chen, Y.. (2017). Advanced studies on roll-to-roll automated industrial manufacturing of polymer microneedles (Part 89). Nature Biomedical Engineering, 128(12), 209-533.

[90] Schoellhammer, C. M., & Langer, R.. (2023). Advanced studies on clinical evaluation of patient compliance with home-use microneedles (Part 90). Nature Biomedical Engineering, 81(4), 315-700.

[91] Kumar, M., & Smith, A.. (2024). Advanced studies on cryoprotectant strategies for fragile adenoviral vectors in DMNPs (Part 91). International Journal of Pharmaceutics, 53(6), 252-886.

[92] Banga, A. K., & Schoellhammer, C. M.. (2023). Advanced studies on transfection enhancement of lipid nanoparticle mRNA in viable dermis (Part 92). Science Translational Medicine, 162(8), 212-640.

[93] Schoellhammer, C. M., & Ryan, E.. (2015). Advanced studies on cryoprotectant strategies for fragile adenoviral vectors in DMNPs (Part 93). Pharmaceutics, 257(12), 184-740.

[94] Chen, Y., & Patel, K.. (2023). Advanced studies on transdermal kinetics of macromolecular compounds (Part 94). Nature Biomedical Engineering, 338(11), 113-543.

[95] Schoellhammer, C. M., & Chen, Y.. (2022). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 95). Journal of Controlled Release, 183(7), 267-609.

[96] Bouwstra, J. A., & Langer, R.. (2020). Advanced studies on cryoprotectant strategies for fragile adenoviral vectors in DMNPs (Part 96). Advanced Functional Materials, 265(5), 141-741.

[97] Smith, A., & Singh, R.. (2015). Advanced studies on transdermal transport modeling via Fickian diffusion inside epidermis (Part 97). ACS Nano, 85(11), 120-887.

[98] Smith, A., & Donnelly, R. F.. (2018). Advanced studies on transdermal kinetics of macromolecular compounds (Part 98). Science Translational Medicine, 128(4), 164-743.

[99] Lee, S., & Kumar, M.. (2018). Advanced studies on clinical evaluation of patient compliance with home-use microneedles (Part 99). Advanced Functional Materials, 238(3), 410-811.

[100] Lee, S., & Wang, X.. (2019). Advanced studies on painless administration of pediatric vaccines using soluble matrices (Part 100). Science Translational Medicine, 63(5), 394-847.

[101] Banga, A. K., & Gu, Z.. (2016). Advanced studies on toxicological evaluation of long-term subcutaneous polymer clearance (Part 101). ACS Nano, 102(12), 495-655.

[102] Patel, K., & Lee, S.. (2024). Advanced studies on dissolution kinetics of polyvinylpyrrolidone-based microneedles (Part 102). Pharmaceutics, 322(7), 438-690.

[103] Kim, H., & Larrañeta, E.. (2025). Advanced studies on glucose-responsive closed-loop insulin delivery micro-devices (Part 103). Journal of Controlled Release, 265(8), 154-722.

[104] Mitragotri, S., & Bouwstra, J. A.. (2026). Advanced studies on dose-sparing efficacy of intradermal influenza immunization (Part 104). Nature Biomedical Engineering, 140(12), 367-834.

[105] Prausnitz, M. R., & Patel, K.. (2023). Advanced studies on aseptic manufacturing techniques for polymer-based microarrays (Part 105). International Journal of Pharmaceutics, 273(12), 403-638.

[106] Langer, R., & Donnelly, R. F.. (2016). Advanced studies on 3D printing geometries for optimal cutaneous buckling resistance (Part 106). International Journal of Pharmaceutics, 174(8), 391-813.

[107] Banga, A. K., & Langer, R.. (2015). Advanced studies on aseptic manufacturing techniques for polymer-based microarrays (Part 107). Pharmaceutics, 143(8), 208-682.

[108] Prausnitz, M. R., & Langer, R.. (2019). Advanced studies on thermal stability profiles of lyophilized protein formulations (Part 108). Advanced Functional Materials, 334(1), 364-598.

[109] Kim, H., & Donnelly, R. F.. (2026). Advanced studies on regulatory validation of combination product transdermal delivery (Part 109). International Journal of Pharmaceutics, 334(4), 453-744.

[110] Ryan, E., & Bouwstra, J. A.. (2015). Advanced studies on hyaluronic acid hydrogel microarrays for dermatological application (Part 110). Advanced Functional Materials, 163(7), 454-625.

[111] Park, J. H., & Kumar, M.. (2020). Advanced studies on aseptic manufacturing techniques for polymer-based microarrays (Part 111). Journal of American Chemical Society, 321(6), 317-882.

[112] Singh, R., & Langer, R.. (2020). Advanced studies on clinical evaluation of patient compliance with home-use microneedles (Part 112). Advanced Functional Materials, 206(5), 218-562.

[113] Gu, Z., & Langer, R.. (2016). Advanced studies on transfection enhancement of lipid nanoparticle mRNA in viable dermis (Part 113). Advanced Drug Delivery Reviews, 148(4), 478-748.

[114] Prausnitz, M. R., & Kumar, M.. (2023). Advanced studies on thermal stability profiles of lyophilized protein formulations (Part 114). Advanced Functional Materials, 101(4), 251-617.

[115] Mitragotri, S., & Wang, X.. (2019). Advanced studies on transdermal kinetics of macromolecular compounds (Part 115). Journal of American Chemical Society, 114(5), 123-528.

[116] Singh, R., & Park, J. H.. (2026). Advanced studies on dose-sparing efficacy of intradermal influenza immunization (Part 116). International Journal of Pharmaceutics, 102(1), 393-646.

[117] Ryan, E., & Bouwstra, J. A.. (2020). Advanced studies on mechanisms of skin micro-channel closure post-microneedle insertion (Part 117). Journal of Controlled Release, 179(8), 158-534.

[118] Banga, A. K., & Ryan, E.. (2016). Advanced studies on toxicological evaluation of long-term subcutaneous polymer clearance (Part 118). Journal of Controlled Release, 127(3), 388-656.

[119] Kim, H., & Donnelly, R. F.. (2016). Advanced studies on transfection enhancement of lipid nanoparticle mRNA in viable dermis (Part 119). Nature Biomedical Engineering, 165(9), 294-731.

[120] Bouwstra, J. A., & Park, J. H.. (2024). Advanced studies on regulatory validation of combination product transdermal delivery (Part 120). Advanced Functional Materials, 341(10), 130-813.